Efficacy and Safety of Lotilaner Ophthalmic Solution (0.25%) for the Treatment of Demodex Blepharitis: A GRADE Assessed Systematic Review and Meta-Analysis of Observational &amp; Experimental Studies

Talha, Muhammad; Haris Ali, Mohammad; Fatima, Eeshal; Nadeem, Arsalan; Ahmed, Abdullah; Nashwan, Abdulqadir J.

doi:10.1016/j.ajo.2024.03.019

American Journal of Ophthalmology

2024

DOI: 10.1016/j.ajo.2024.03.019

|View full text |Cite

Efficacy and Safety of Lotilaner Ophthalmic Solution (0.25%) for the Treatment of Demodex Blepharitis: A GRADE Assessed Systematic Review and Meta-Analysis of Observational & Experimental Studies

Muhammad Talha,

Mohammad Haris Ali,

Eeshal Fatima

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Lotilaner ophthalmic solution 0.25% in Demodex blepharitis: a profile of its use

Syed

2024

Drugs Ther Perspect

View full text Add to dashboard Cite

Lotilaner ophthalmic solution 0.25% in Demodex blepharitis: a profile of its use

Syed

2024

Drugs Ther Perspect

View full text Add to dashboard Cite

Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis

Davey,

Farid,

Karpecki

et al. 2024

Healthcare

View full text Add to dashboard Cite

Demodex blepharitis, a chronic lid margin disease, is caused by an infestation of Demodex mites, the most common ectoparasites in human skin and eyelids. Lotilaner ophthalmic solution, 0.25% (Xdemvy, Tarsus Pharmaceuticals), is the first therapy approved to treat Demodex blepharitis. This narrative review characterizes lotilaner ophthalmic solution, 0.25%, and describes its efficacy, safety, and tolerability. The safety and efficacy of lotilaner ophthalmic solution, 0.25%, for treating Demodex blepharitis was evaluated in four phase 2 and two phase 3 trials. The data of 980 patients included in these phase 2 and 3 clinical trials revealed that the proportion of eyes with a clinically meaningful reduction to 10 or fewer collarettes (the cylindrical, waxy debris found at the base of the eyelashes) ranged from 81 to 93%. The mite eradication rate confirmed by a microscopy of epilated lashes ranged from 52 to 78%. No serious treatment-related adverse events were reported in any of these clinical studies. As high as 92% of the patients receiving lotilaner eyedrops in the phase 3 trials found it to be neutral to very comfortable. Given the positive safety and efficacy outcomes, the drug is likely to become the standard of care in the treatment of Demodex blepharitis.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Efficacy and Safety of Lotilaner Ophthalmic Solution (0.25%) for the Treatment of Demodex Blepharitis: A GRADE Assessed Systematic Review and Meta-Analysis of Observational & Experimental Studies

Cited by 2 publications

References 32 publications

Lotilaner ophthalmic solution 0.25% in Demodex blepharitis: a profile of its use

Lotilaner ophthalmic solution 0.25% in Demodex blepharitis: a profile of its use

Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis

Contact Info

Product

Resources

About